Clinical experience with Ro 5-3350 (bromazepam).

Area of Science:

• Psychopharmacology
• Clinical Psychology
• Neuroscience

Background:

• Obsessive-compulsive and phobic symptoms represent significant challenges in mental health treatment.
• Anxiolytic medications are crucial for managing anxiety disorders, necessitating evaluation of their efficacy and safety.
• Previous research indicated potential benefits of Ro 5-3350, prompting further investigation.

Purpose of the Study:

• To compare the efficacy of Ro 5-3350 (bromazepam) against chlordiazepoxide in patients with obsessive-compulsive and phobic symptoms.
• To assess the effectiveness of Ro 5-3350 across different anxiety symptom presentations.
• To evaluate the safety and tolerability of Ro 5-3350, including its use during pregnancy.

Main Methods:

• A pilot study was followed by a double-blind trial involving 25 patients (inpatients and outpatients).
• Patients with a history of obsessive-compulsive or phobic symptoms were treated sequentially with Ro 5-3350 and chlordiazepoxide.
• Treatment response was measured using the visual analogue scale, Taylor Manifest Anxiety Scale, and clinical ratings.

Main Results:

• Across all assessment methods, patients consistently favored Ro 5-3350 over chlordiazepoxide.
• Phobic patients showed uniformly favorable responses to Ro 5-3350.
• Two patients receiving long-term Ro 5-3350 treatment completed pregnancy without adverse effects on newborns.

Conclusions:

• Ro 5-3350 (bromazepam) is a potent anxiolytic, particularly effective for visceral anxiety manifestations.
• The medication demonstrated a favorable efficacy profile compared to chlordiazepoxide for the studied patient population.
• Ro 5-3350 exhibited a low incidence of side-effects and no reported toxicity, including during pregnancy.